Commentary
par
Pytell, Jarratt D. & Darious A. Rastegar
Date de publication
2020
Géographie
USA
Langue de la ressource
English
Texte disponible en version intégrale
Oui
Open Access / OK to Reproduce
Oui
Évalué par des pairs
Unknown
L’objectif
We discuss how COVID-19 has ended the practice of “routine” UDT in office-based opioid treatment (OBOT), encouraged a more patient-centered approach, and why targeted, as opposed to routine, UDT should be a lesson learned for practitioners from this pandemic
Constatations/points à retenir
Routine UDS is costly, has environmental implications, may cause harms when results dictate treatment decisions, may case long-term stable patients to feel untrusted. Targeted UDT is helpful when evaluating a patient who is exhibiting potentially toxic effects of an unknown substance, to help guide treatment initiation for opioid agonist or antagonist therapy, or for those patients who want or would benefit from the positive reinforcement of UDT.
Mots clés
Evidence base
Policy/Regulatory
About prescribers
